UB-VV111是一种基于Umoja的VivoVec平台的慢病毒载体基因疗法。UB-VV111编码一个针对CD19 CAR的转基因和一个雷帕霉素激活的细胞因子受体(RACR™),旨在体内丰富和扩大UB-VV111工程化的CAR T细胞。UB-VV111正在被研究用于一系列B细胞恶性肿瘤,包括大B细胞淋巴瘤和慢性淋巴细胞白血病。 UB-VV111的I期研究将是一项...
药品名称 UB-VV111 药品类别 创新药; 生物; 细胞疗法; potential first-in-class; CGT; T细胞; CAR T细胞疗法 靶点 cluster of differentiation 19 (CD19) 作用机制 CAR T细胞疗法 药品简介 UB-VV11 comprises VivoVec particles for in vivo delivery of payloads that include Umoja BioPharma's RAC...
UB-VV111 is potentially the first in situ generated CD19 chimeric antigen receptor (CAR)-T cell therapy to be evaluated in humans in the hematology setting ...
[视频]天宫神八交会对接:严密监测 避免空间碎片袭击2011-11-07 08:00:37 [视频]天宫神舟第二次太空交会对接部分细节披露:光照条件比较恶劣 挑战更2011-11-07 07:59:27 [视频]时政要闻2011-11-07 07:51:51 [视频]时政要闻2011-11-07 07:51:23 [视频]运费涨 煤价高 推高供暖成本2011-11-07 07:42:21...